SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: bodish who wrote (63190)7/26/2025 3:35:58 PM
From: ghettogoulash3 Recommendations

Recommended By
bodish
erippetoe
Olecranon

   of 63277
 
Fwiw, Ingram said in May that it was the FDA who suggested adding Sirolimus to the protocol in non-ambulatory, presumably after the first death. Seems like a steep hill to climb now in that indication, however. Regarding the death in Brazil, a pharma reporter from CNBC posted this:

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News